Late July has compressed: MNKD’s weekend clock, OTLK’s Class 1 review, VTRS’s 505(b)(2) patch and REPL’s newly confirmed July 30 AdCom now sit inside five calendar days.
The late-July cluster splits across evidence and label scope, delivery-format execution, Class 1 closeout and AdCom-led evidence adequacy. MRNA adds an age-split vaccine pathway; LNTH adds diagnostic-performance and label risk.
| Date | Ticker / Event | Setup / Risk | PoA |
| Fri Jul 17 |
CELC gedatolisib / HR+ HER2- PIK3CA WT ABC |
Priority / RTOR Evidence / label scope |
87% |
| Sun Jul 26 |
MNKD FUROSCIX ReadyFlow Autoinjector |
Delivery sNDA Device / execution |
73% |
| Wed Jul 29 |
OTLK LYTENAVA / wet AMD |
Scarred Class 1 Label / closeout |
85% |
| Thu Jul 30 |
VTRS MR-100A-01 weekly patch |
505(b)(2) NDA Efficacy / BMI / adhesion |
90% |
| Thu Jul 30 |
REPL RP1 + nivolumab CTGTAC |
AdCom watch Evidence adequacy |
ADCOM |
| Sun Aug 2 |
REPL RP1 + nivolumab / melanoma |
Class 1 response Evidence adequacy |
19% |
| Wed Aug 5 |
MRNA MFLUSIVA / mRNA-1010 |
Post-AdCom BLA Age-split pathway |
85% |
| Thu Aug 13 |
LNTH MK-6240 tau PET imaging |
Fast Track NDA Performance / label |
88% |
✓ | VERA / TRUTAKNA — ACCELERATED APPROVAL · JUL 7 FDA approved atacicept-vymj to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. The binary resolved; the confirmatory clock remains open. |
→ | CELC — NOW FRONT BOARD Gedatolisib is the next hard clock on Friday. Keep the submitted population narrow: HR+/HER2-/PIK3CA wild-type advanced breast cancer after prior CDK4/6 inhibitor plus aromatase-inhibitor therapy. |
! | REPL — CTGTAC ADCOM LOCKED FOR JUL 30 FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee now lands three calendar days before the Aug. 2 action goal. The briefing documents and vote can move the setup before the PDUFA date does. |
| CELC$CELC · gedatolisib | Fri Jul 17 PoA 87% |
CELC is the next hard clock. The NDA is based on the PIK3CA wild-type VIKTORIA-1 cohort after progression on or after a CDK4/6 inhibitor plus an aromatase inhibitor. Both evaluated regimens produced statistically significant PFS results, but the exact proposed-label wording is not public.
| REPL$REPL · RP1 + nivolumab | AdCom Jul 30 PoA 19% |
The AdCom is now the primary catalyst. FDA’s prior CRLs focused on substantial evidence of effectiveness, including RP1’s contribution to the combination, population heterogeneity and uncertainty around response assessment.
REPL’s committee meeting is July 30. Its FDA goal date is Aug. 2.
The briefing package can change the setup before the panel meets, and the vote lands only three calendar days before the action goal. Treat the AdCom as the live event—not a footnote to the PDUFA date.
| CELC | Efficacy package, population or regimen narrowing, or a separate safety/CMC problem? |
| MNKD | Device and delivery execution rather than the established furosemide thesis? |
| OTLK | Label or closeout failure, or an issue thought resolved through dispute resolution? |
| VTRS | Contraceptive efficacy, BMI-restricted population, adhesion, PK or safety language? |
| REPL | Did the package still fail to establish effectiveness or isolate RP1’s contribution? |
The board is heavier now, but the risk is sorted.
Resolved: VERA / TRUTAKNA.
Live: CELC → MNKD → OTLK / VTRS / REPL AdCom → REPL → MRNA → LNTH.
Highest-drama name: REPL, because the evidence debate becomes public only three days before the FDA goal date.
Informational only · Not investment advice · Biotech carries risk of total loss